Raymond James & Associates Pds Biotechnology Corp Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Raymond James & Associates holds 11,731 shares of PDSB stock, worth $13,842. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,731
Previous 13,852
15.31%
Holding current value
$13,842
Previous $40,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PDSB
# of Institutions
59Shares Held
4.22MCall Options Held
170KPut Options Held
6.7K-
Vanguard Group Inc Valley Forge, PA1.51MShares$1.78 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$574,6210.0% of portfolio
-
Geode Capital Management, LLC Boston, MA417KShares$492,3160.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA247KShares$291,4320.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il220KShares$259,8530.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $33.6M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...